Rynomistyn® (Medicinal Product)

Composition:

Active ingredients: Xylometazoline, Miramistin

1 ml of solution contains:

Xylometazoline hydrochloride: 0.5 mg or 1 mg

Miramistin (calculated as anhydrous substance): 0.1 mg

Dosage Form: Nasal drops, solution

Pharmacotherapeutic Group: Decongestants and other nasal preparations for topical use. Sympathomimetics in combination with other agents.

ATC Code: R01A B06

Pharmacological Properties:

• Xylometazoline: A local adrenergic agonist. It causes vasoconstriction of the nasal mucosa blood vessels, reducing hyperemia and swelling, and decreasing exudation. The action begins within 10–15 minutes, lasts for 5–6 hours, and the vasoconstriction effect continues for 8–12 hours.
• Miramistin: An antiseptic that directly interacts with the lipids of microbial cell membranes. This leads to membrane disruption, increased permeability to high-molecular-weight substances, and disruption of enzymatic activity, ultimately inhibiting the viability of microorganisms and causing cytolysis.

Miramistin exhibits high selectivity, targeting microorganisms without significantly affecting human cell membranes. It is active against Gram-positive and Gram-negative bacteria, aerobic and anaerobic microorganisms, spore-forming and non-spore-forming bacteria, including hospital strains resistant to antibiotics.

Under the influence of Miramistin, microbial resistance to antibiotics is reduced. Additionally, Miramistin provides anti-inflammatory and immune-adjuvant effects, enhances local protective responses, promotes regenerative processes, and activates mechanisms of non-specific immunity by modulating cellular and humoral immune responses.

Rinomistin® has a balanced pH suitable for the nasal cavity. Its optimal composition prevents dryness and irritation of the mucosa, facilitates mucus drainage, and does not impair the ciliary activity of nasal epithelial cells.

Indications:

• Acute and chronic forms of rhinitis, sinusitis, and rhinosinusitis accompanied by nasal congestion and complicated by microbial infection.
• As part of combination therapy for acute otitis media and eustachitis (to restore the patency of the eustachian tube).
• Prevention of infectious complications during rhinoscopy and other manipulations in the nasopharyngeal area.
  

Packaging: 10 ml in polymer bottles with a dropper. One bottle per carton box.

Country of Manufacture: Ukraine

Marketing and Distribution in Ukraine: LLC "Valartin-Pharma"

For more detailed information, refer to the instructions for medical use of Rynomistyn®.